The involvement of DLD, ALDH1B1, and HADH in these essential metabolic pathways, along with their associations with treatment response 42-44, highlights their potential as prognostic biomarkers in NPC, offering valuable insights for clinical management and personalized therapy. Here, HADH is linked to nasopharyngeal carcinoma.